Methods and compositions for improving cognitive function

Abstract

This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment.

1 - 103 . (canceled) 
     
     
         104 . A method for treating cognitive impairment, for delaying or slowing the progression of said cognitive impairment, or for reducing the rate of decline of cognitive function, in a subject having or at risk of having said cognitive impairment or decline of cognitive function, the method comprising administering to said subject levetiracetam, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, or prodrug thereof, at a daily dose of 0.1 mg-350 mg,
 wherein the cognitive impairment or decline of cognitive function accompanies mental retardation, Parkinson's disease, autism, compulsive behavior, or substance addiction.   
     
     
         105 - 123 . (canceled) 
     
     
         124 . The method of  claim 104 , wherein the levetiracetam, or the pharmaceutically acceptable salt, hydrate, solvate, polymorph, or prodrug thereof, is administered in an extended release form. 
     
     
         125 - 179 . (canceled) 
     
     
         180 . The method of  claim 104 , wherein the effect of the treatment, the progression of cognitive impairment, or the rate of decline of cognitive function is measured by the Clinical Dementia Rating Scale. 
     
     
         181 . The method of  claim 104 , wherein the effect of the treatment, the progression of cognitive impairment, or the rate of decline of cognitive function is measured by detecting the difference between the levels of reelin in the subject prior to and after the administration step. 
     
     
         182 . The method of  claim 104 , wherein the effect of the treatment, the progression of cognitive impairment, or the rate of decline of cognitive function is measured by detecting the difference between the levels of somatostatin in the subject prior to and after the administration step. 
     
     
         183 . The method of  claim 124 , wherein the extended release form is a controlled release form, a prolonged release form, a sustained release form, a delayed release form, or a slow release form.